Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Heterocyclic anthracene ketone histone methyltransferase inhibitor and medical application thereof

A heterocycle and methoxy technology, applied in the field of medicinal chemistry, can solve problems that have not been studied clearly

Inactive Publication Date: 2015-12-30
CHINA PHARM UNIV
View PDF2 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, the specific mechanism of histone lysine methylation affecting gene transcription has not been studied clearly, and its more biological functions need to be further elucidated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Heterocyclic anthracene ketone histone methyltransferase inhibitor and medical application thereof
  • Heterocyclic anthracene ketone histone methyltransferase inhibitor and medical application thereof
  • Heterocyclic anthracene ketone histone methyltransferase inhibitor and medical application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Preparation of 3,5-dibromo-6H-anthracene[1,9-cd]isoxazol-6-one

[0053]

[0054] 6H-Anthracene[1,9-cd]isoxazol-6-one (5g, 22.60mmol) was dissolved in AcOH (50mL), and bromine (2.90mL, 56.51mmol) in acetic acid solution was added dropwise to the reaction solution During TLC detection, the reaction was terminated. The reaction solution was adjusted to weak alkalinity with saturated sodium bicarbonate, extracted with dichloromethane (3×50 mL), the organic layer was dried with anhydrous sodium sulfate, the solvent was spin-dried, and the yellow 3,5-bis Bromo-6H-anthracene[1,9-cd]isoxazol-6-one (7.26g, 73%).m.p.247-248℃. 1 HNMR (300MHz, CDCl 3 ): δ8.45(d, J=7.71Hz, 1H, ArH), 8.08(d, J=7.5Hz, 1H, ArH), 7.97(s, 1H, ArH), 7.82(t, J=7.23Hz, 1H,ArH),7.72(t,J=7.35Hz,ArH).HRMS(ESI):calcdforC 14 h 5 Br 2 NO 2 [M+H] + 377.8760,found 377.8752.

Embodiment 2

[0056]

[0057] Differently substituted ammonia was dissolved in anhydrous aluminum chloride in dichloromethane solution, the compound of Example 1 was added to the mixture, stirred at 40° C. for 12 h, detected by TLC, and the reaction was stopped. The reaction was extracted with water (2 x 30 mL). The organic layer was dried with anhydrous sodium sulfate, and the solvent was spin-dried to obtain a red solid.

Embodiment 3

[0060] Preparation of 3-bromo-5-((4-methoxyphenyl)amino)-6H-anthracene[1,9-cd]isoxazol-6-one

[0061]

[0062] 3,5-dibromo-6H-anthracene[1,9-cd]isoxazol-6-one (0.10g, 0.26mmol) and p-methoxyaniline (0.19g, 1.58mmol) were synthesized according to the method in Example 2 . m.p.156-157℃. 1 HNMR (300MHz, CDCl 3 ):δ11.32(s,1H,NH),8.58(d,J=7.23Hz,1H,ArH),8.18(d,J=7.23Hz,ArH),7.82(t,J=7.47Hz,1H, ArH), 7.70(t, J=8.01Hz, 1H, ArH), 7.62(s, 1H, ArH), 7.30(d, J=8.79Hz, 2H, ArH), 7.05(d, J=8.85Hz, 2H ,ArH),3.91(s,3H,CH3).HRMS(ESI):calcdforC 21 h 13 BrN 2 o 3 [M+H] + 421.0182,found 421.0186.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicinal chemistry, in particular to a heterocyclic anthracene ketone histone methyltransferase inhibitor and a preparation method and application of the heterocyclic anthracene ketone histone methyltransferase inhibitor. It is proved by pharmacology experiments that the compound has a good inhibiting effect on histone methyltransferase from the molecular level to the cell level, has good antiproliferative activity on tumor cell strains and has reasonable medicinal parameters, such as a proper dissociation constant (pKa), a lipid-aqueous partition coefficient (LogD, pH=7.4), water solubility and film transmittance. It is testified by research on pharmacokinetics that the compound is wide in distribution in a body of a rat, the plasma clearance can be within an acceptable range, and good bioavailability is achieved. The compound and the pharmaceutic preparation of the compound can be used for treating a series of diseases caused by disorder of enzyme activity of the histone methyltransferase, such as solid tumor, leucocythemia, malaria and neurodegenerative diseases.

Description

technical field [0001] The invention relates to the field of medicinal chemistry, in particular to a class of heterocyclic anthrone-type histone methyltransferase inhibitors, a preparation method and medical application thereof. Background technique [0002] Histone methylation modification is an important epigenetic regulation mode, which is involved in the regulation of chromatin conformation, gene transcription and expression. The methylation level of histone is closely related to a variety of proto-oncogenes and tumor suppressor genes. The abnormal expression of these proto-oncogenes and tumor suppressor genes may lead to the occurrence of tumors. Therefore, by regulating the methylation level of histones, some important genes can be transcribed to achieve the purpose of treating tumors. Histone methylation regulatory proteins have become the latest and most popular targets in the field of cancer drug development. [0003] The main substrates of histone methyltransfera...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D261/20C07D413/04A61K31/454A61K31/496A61K31/551A61P35/00A61P35/02A61P25/00A61P33/06
CPCC07D261/20C07D413/04Y02A50/30
Inventor 尤启冬孙昊鹏陈维琳郭小可冯涛涛李冬冬张晓进徐晓莉姜正羽
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com